CJC-1295 – With DAC (5mg)

CJC-1295 with DAC is the albumin-conjugating version of CJC-1295, featuring a Drug Affinity Complex (DAC) — a reactive maleimidopropionic acid group that forms a covalent bond with serum albumin after subcutaneous injection. This albumin conjugation dramatically extends the circulating half-life from approximately 30 minutes (without DAC) to 6-8 days, enabling sustained elevation of GH and IGF-1 from a single administration. Once bound to albumin, the CJC-1295-DAC conjugate circulates with the albumin protein, slowly releasing active peptide that continuously stimulates GHRH receptors on pituitary somatotrophs. This produces a pattern of sustained GH elevation rather than the acute pulsatile pattern seen with the non-DAC version. Teichman et al. demonstrated in a landmark clinical study that a single injection produced dose-dependent GH increases sustained for up to 6 days and IGF-1 elevation for 9-11 days. The sustained-release pharmacokinetics of CJC-1295 DAC are advantageous for research protocols requiring consistent GH/IGF-1 elevation, but some researchers prefer the non-DAC version because it better preserves the natural pulsatile GH secretion pattern. The choice between versions depends on the specific research question being addressed.

CJC-1295 with DAC is the albumin-conjugating version of CJC-1295, featuring a Drug Affinity Complex (DAC) — a reactive maleimidopropionic acid group that forms a covalent bond with serum albumin after subcutaneous injection. This albumin conjugation dramatically extends the circulating half-life from approximately 30 minutes (without DAC) to 6-8 days, enabling sustained elevation of GH and IGF-1 from a single administration. Once bound to albumin, the CJC-1295-DAC conjugate circulates with the albumin protein, slowly releasing active peptide that continuously stimulates GHRH receptors on pituitary somatotrophs. This produces a pattern of sustained GH elevation rather than the acute pulsatile pattern seen with the non-DAC version. Teichman et al. demonstrated in a landmark clinical study that a single injection produced dose-dependent GH increases sustained for up to 6 days and IGF-1 elevation for 9-11 days. The sustained-release pharmacokinetics of CJC-1295 DAC are advantageous for research protocols requiring consistent GH/IGF-1 elevation, but some researchers prefer the non-DAC version because it better preserves the natural pulsatile GH secretion pattern. The choice between versions depends on the specific research question being addressed.

Clinical studies used single subcutaneous doses of 30-60 mcg/kg. Due to the long half-life, dosing frequency in research is typically once weekly.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.